Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study
Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study
复制标题
DOI：
10.1136/annrheumdis-2016-210775
复制
发表时间：
2017-08-01
影响因子：
27.4
通讯作者：
Van den Bosch, Filip
中科院分区：
文献类型：
--
作者：
Carron, Philippe;Varkas, Gaelle;Van den Bosch, Filip
目的 评价戈利木单抗诱导极早期活动性周围型脊柱关节炎 (pSpA) 患者临床缓解的有效性和安全性。方法 周围型脊柱关节炎临床缓解是一项戈利木单抗治疗 pSpA 患者的单中心研究。所有患者均符合国际脊柱关节炎评估协会对 pSpA 的分类标准，症状持续时间
Objective To evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA).Methods Clinical REmission in peripheral SPondyloArthritis is a monocentric study of golimumab treatment in patients with pSpA. All patients fulfilled the Assessment of SpondyloArthritis international Society classification criteria for pSpA, with a symptom duration